Keytruda (pembrolizumab) received FDA approval for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
